Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Free Cash Flow (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Free Cash Flow for 10 consecutive years, with -$100.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 26.79% to -$100.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$472.0 million, a 12.11% decrease, with the full-year FY2025 number at -$472.0 million, down 12.11% from a year prior.
  • Free Cash Flow was -$100.8 million for Q4 2025 at Ultragenyx Pharmaceutical, down from -$92.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$16.3 million in Q4 2021 to a low of -$192.0 million in Q1 2024.
  • A 5-year average of -$106.7 million and a median of -$96.7 million in 2025 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 66.76% in 2021; the steepest drop was 202.59% in 2021.
  • Ultragenyx Pharmaceutical's Free Cash Flow stood at -$16.3 million in 2021, then decreased by 17.55% to -$19.2 million in 2022, then plummeted by 168.54% to -$51.4 million in 2023, then plummeted by 54.53% to -$79.5 million in 2024, then decreased by 26.79% to -$100.8 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Free Cash Flow are -$100.8 million (Q4 2025), -$92.7 million (Q3 2025), and -$110.5 million (Q2 2025).